Pharmaceutical strategies in the emerging era of antibody-based biotherapeutics for the treatment of cancers overexpressing MET receptor tyrosine kinase.

Hang-Ping Yao Xiang-Min Tong Ming-Hai Wang

Drug Discov Today

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; National Clinical Research Center for Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Cancer Biology Research Center, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA; Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA. Electronic address:

Published: January 2021

Pharmaceutical innovation in the development of novel antibody-based biotherapeutics with increased therapeutic indexes makes MET-targeted cancer therapy a clinical reality.

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.drudis.2020.11.002	DOI Listing

Publication Analysis

Top Keywords

antibody-based biotherapeutics

pharmaceutical strategies

strategies emerging

emerging era

era antibody-based

biotherapeutics treatment

treatment cancers

cancers overexpressing

overexpressing met

met receptor

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!